A nonrandomized, prospective, clinical study on the impact of circulating tumor cells on outcomes of urothelial carcinoma of the bladder patients treated with radical cystectomy with or without adjuvant chemotherapy

2016 ◽  
Vol 140 (2) ◽  
pp. 381-389 ◽  
Author(s):  
Armin Soave ◽  
Sabine Riethdorf ◽  
Roland Dahlem ◽  
Gunhild von Amsberg ◽  
Sarah Minner ◽  
...  
Keyword(s):  
Clinical Study ◽  
Adjuvant Chemotherapy ◽  
Urothelial Carcinoma ◽  
Tumor Cells ◽  
Radical Cystectomy ◽  
Circulating Tumor Cells ◽  
Prospective Clinical Study ◽  
Carcinoma Of The Bladder ◽  
The Impact

scholarly journals The Impact of Circulating Tumor Cells on Venous Thromboembolism and Cardiovascular Events in Bladder Cancer Patients Treated with Radical Cystectomy

2020 ◽  
Vol 9 (11) ◽  
pp. 3478
Author(s):  
Michael Rink ◽  
Sabine Riethdorf ◽  
Hang Yu ◽  
Mara Kölker ◽  
Malte W. Vetterlein ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Tumor Cells ◽  
Radical Cystectomy ◽  
Circulating Tumor Cells ◽  
Cardiovascular Events ◽  
Comprehensive Complication Index ◽  
Increased Risk ◽  
Relevant Risk Factor ◽  
Carcinoma Of The Bladder ◽  
The Impact

Background: Cancer is a relevant risk factor for venous thromboembolism (VTE). Circulating tumor cells (CTC) are associated with an increased risk of VTE in breast cancer. In addition, circulating cell-free nucleic acids have been associated with cardiovascular events (CVE). Objective: To investigate the association of CTC status and the risk of VTE as well as CVE in urothelial carcinoma of the bladder (UCB) patients treated with radical cystectomy (RC). Methods: We collected data of 189 UCB patients treated with RC at our institution. Blood samples were acquired preoperatively and analyzed for CTC using the CellSearch® system. Thirty-day postoperative complications were extracted from digital charts and graded according to the Clavien–Dindo classification (CDC). Moreover, each patient’s individual Comprehensive Complication Index® (CCI®) was calculated. Results: CTC were present in 43 patients (22.8%). Overall, six patients experienced VTE (3.2%) and eight patients (4.2%) experienced CVE. There was no association of VTE or CVE according to CTC status. In total, 168 patients (89%) experienced a total of 801 complications, of which the majority was classified as “minor” (CDC grade ≤ IIIa; 79%). There was no association between CTC status and any grade of a complication or CCI®. Presence of CTC was associated with more aggressive clinicopathological UCB features. Conclusions: The overall rate of VTE and CVE was low in our study. Presence of CTC was neither associated with an increased risk of VTE nor CVE in UCB patients treated with RC. According to this study, CTC are not a qualified biomarker for individualized thromboprophylaxis management in these patients.

scholarly journals Variant Histology: The Impact on Oncological Outcomes of Patients with Urothelial Carcinoma of The Bladder Treated with Radical Cystectomy

2021 ◽  
Vol 8 (4) ◽  
pp. 243-247
Author(s):  
Berk Hazır ◽  
Hakan Bahadır Haberal ◽  
Kadir Emre Baltacı ◽  
Parviz Shahsuvarli ◽  
Bülent Akdoğan ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Radical Cystectomy ◽  
Oncological Outcomes ◽  
Variant Histology ◽  
Carcinoma Of The Bladder ◽  
The Impact

Prospective clinical study of circulating tumor cells for colorectal cancer screening.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 556-556 ◽  
Author(s):  
Wen-Sy Tsai ◽  
Ashish Nimgaonkar ◽  
Oscar Segurado ◽  
Ying Chang ◽  
Ben Hsieh ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Study ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Precancerous Lesions ◽  
Specific Binding ◽  
Detection Methods ◽  
Prospective Clinical Study ◽  
Screening Methods ◽  
Blood Draw

556 Background: Colorectal cancer (CRC) is among the most preventable cancers when precancerous lesions are detected at an early stage. Current screening methods for CRC require bowel prep or stool-based testing that are inconvenient, resulting in low compliance. Stool based tests have limited sensitivity for the detection of precancerous lesions. We have conducted a prospective clinical study over a period of > 3 years to assess a novel assay to detect and enumerate circulating tumor cells (CTCs) in a blood sample for early CRC detection. Methods: A single-center, IRB-approved, prospective and blinded clinical study was conducted in 620 subjects including 438 with adenoma, polyps or stage I-IV CRC and 182 healthy controls. For each subject, 2mL peripheral whole blood collected through a routine blood draw was processed using the CellMax biomimetic platform (CMx). The CMx test is a proprietary microfluidic biochip that minimizes non-specific binding and accurately enumerates CTCs. A multivariate analysis was performed to assess the clinical performance characteristics of the CMx test. Results: Disease status was evaluated by a standard clinical protocol which included colonoscopy and biopsy results. Probability of CRC risk was assessed by an age-adjusted regression model which correlated CTCs to clinical status. The CMx test’s overall accuracy was 88% for all stages of colorectal illness, including precancerous lesions. Conclusions: The study has demonstrated high accuracy for the detection of CRC using a novel CTC assay. It is the first study to show high sensitivity in the detection of precancerous colorectal lesions. The simple blood draw required can be easily integrated into a patient’s routine physical, increasing test compliance.[Table: see text]

Do Circulating Tumor Cells Have a Role in Deciding on Adjuvant Chemotherapy After Radical Cystectomy?

2015 ◽  
Vol 16 (7) ◽  
Author(s):  
Armin Soave ◽  
Sabine Riethdorf ◽  
Klaus Pantel ◽  
Margit Fisch ◽  
Michael Rink
Keyword(s):  
Adjuvant Chemotherapy ◽  
Tumor Cells ◽  
Radical Cystectomy ◽  
Circulating Tumor Cells
Sign in / Sign up

Export Citation Format

Share Document